Entities / Person
MRK.
Visual artist and director.
- Reports this week
- 0
- Active events
- 0
- Connections
- 14
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Cidara Therapeutics was discussed alongside peer groups in the market, involving MRK.Some support1 report1 development inside
-
Revolution Medicines, Inc. is advancing its late-stage RAS(ON) pipeline, gaining FDA priority review, and is seen as a potential acquisition target for MRK.Some support1 report
Gone quiet
No new reports in 90+ days-
The FDA has granted expanded use and new indications for products manufactured by MRK.Some support1 report
-
MRK Animal Health operates in the U.S., and Rob Armstrong works for the company.Some support4 reports
-
FDA granted approval and accepted sNDA for Bristol-Myers Squibb drugs, alongside EMA validation and a collaboration agreement with Merck.Some support2 reports
-
Goldman Sachs reduced its price target on MRK stock, while the company anticipates supportive data from a Hyperion trial.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around MRK this week
News at the entities that move MRK most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves MRK
Connections
The 3 strongest of 14, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA acts as the primary market gatekeeper, granting necessary approvals and indications for MRK products to operate commercially.
-
Cidara Therapeutics Operational
The relationship is characterized by active market competition, discussed alongside peer groups.
-
representative Transactional
Representative purchased shares of MRK.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
4 events- The FDA has granted expanded use and new indications for products manufactured by MRK.
- MRK Animal Health operates in the U.S., and Rob Armstrong works for the company.
- FDA granted approval and accepted sNDA for Bristol-Myers Squibb drugs, alongside EMA validation and a collaboration agreement with Merck.
- Goldman Sachs reduced its price target on MRK stock, while the company anticipates supportive data from a Hyperion trial.